Doris Benbrook to Administration, Oral
This is a "connection" page, showing publications Doris Benbrook has written about Administration, Oral.
Connection Strength
0.476
-
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570.
Score: 0.138
-
Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila). 2013 Sep; 6(9):908-16.
Score: 0.101
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
Score: 0.083
-
Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008.
Score: 0.040
-
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
Score: 0.040
-
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13(4):e0194046.
Score: 0.035
-
Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol. 2013 Jul; 36(3):284-95.
Score: 0.024
-
High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov; 58(5):561-9.
Score: 0.015